PMID- 26899129
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20181113
IS  - 1873-7544 (Electronic)
IS  - 0306-4522 (Print)
IS  - 0306-4522 (Linking)
VI  - 322
DP  - 2016 May 13
TI  - Role of TrkB in the anxiolytic-like and antidepressant-like effects of vagal 
      nerve stimulation: Comparison with desipramine.
PG  - 273-86
LID - S0306-4522(16)00147-0 [pii]
LID - 10.1016/j.neuroscience.2016.02.024 [doi]
AB  - A current hypothesis regarding the mechanism of antidepressant (AD) action 
      suggests the involvement of brain-derived neurotrophic factor (BDNF). Consistent 
      with this hypothesis, the receptor for BDNF (and neurotrophin 4/5 (NT-4/5)), 
      Tropomyosin-related kinase B (TrkB), is activated in rodents by treatment with 
      classical AD drugs. Vagal nerve stimulation (VNS), a therapy for treatment 
      resistant depression (TRD), also activates TrkB in rodents. However, the role of 
      this receptor in the therapeutic effects of VNS is unclear. In the current study, 
      the involvement of TrkB in the effects of VNS was investigated in rats using its 
      inhibitor, K252a. Anxiolytic-like and AD-like effects were analyzed using the 
      novelty suppressed feeding test (NSFT) and forced swim test (FST), respectively. 
      K252a blocked the anxiolytic-like effect of chronic VNS treatment and the AD-like 
      effect of acute VNS treatment. By contrast, blocking TrkB did not prevent either 
      the anxiolytic-like or AD-like effect of chronic treatment with desipramine 
      (DMI), a selective noradrenergic reuptake inhibitor; it did, however, block the 
      acute effect of DMI in the FST. To examine whether the activation of TrkB caused 
      by either VNS or DMI is ligand-dependent, use was made of TrkB-Fc, a molecular 
      scavenger for ligands of TrkB. Intraventricular administration of TrkB-Fc blocked 
      the acute activation of TrkB induced by either treatment, indicating that 
      treatment-induced activation of this receptor is ligand-dependent. The behavioral 
      results highlight differences in the involvement of TrkB in the chronic effects 
      of an AD drug and a stimulation therapy as well as its role in acute versus 
      chronic effects of DMI.
CI  - Copyright (c) 2016 IBRO. All rights reserved.
FAU - Shah, A P
AU  - Shah AP
AD  - Department of Pharmacology and Center for Biomedical Neuroscience, University of 
      Texas Health Science Center at San Antonio, TX, USA. Electronic address: 
      ashah69@jhmi.edu.
FAU - Carreno, F R
AU  - Carreno FR
AD  - Department of Pharmacology and Center for Biomedical Neuroscience, University of 
      Texas Health Science Center at San Antonio, TX, USA.
FAU - Wu, H
AU  - Wu H
AD  - Department of Pharmacology and Center for Biomedical Neuroscience, University of 
      Texas Health Science Center at San Antonio, TX, USA.
FAU - Chung, Y A
AU  - Chung YA
AD  - Department of Pharmacology and Center for Biomedical Neuroscience, University of 
      Texas Health Science Center at San Antonio, TX, USA.
FAU - Frazer, A
AU  - Frazer A
AD  - Department of Pharmacology and Center for Biomedical Neuroscience, University of 
      Texas Health Science Center at San Antonio, TX, USA; South Texas Veterans Health 
      Care System (STVHCS), Audie L. Murphy Division, San Antonio, TX, USA.
LA  - eng
GR  - R01 MH082933/MH/NIMH NIH HHS/United States
GR  - MH082933/MH/NIMH NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20160216
PL  - United States
TA  - Neuroscience
JT  - Neuroscience
JID - 7605074
RN  - 0 (Adrenergic Uptake Inhibitors)
RN  - 0 (Anti-Anxiety Agents)
RN  - 0 (Antidepressive Agents, Tricyclic)
RN  - 0 (Carbazoles)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Indole Alkaloids)
RN  - 97161-97-2 (staurosporine aglycone)
RN  - EC 2.7.10.1 (Receptor, trkB)
RN  - TG537D343B (Desipramine)
SB  - IM
MH  - Adrenergic Uptake Inhibitors/pharmacology
MH  - Animals
MH  - Anti-Anxiety Agents/pharmacology
MH  - Antidepressive Agents, Tricyclic/pharmacology
MH  - Anxiety Disorders/*metabolism/*therapy
MH  - Carbazoles/pharmacology
MH  - Depressive Disorder/*metabolism/*therapy
MH  - Desipramine/pharmacology
MH  - Disease Models, Animal
MH  - Enzyme Inhibitors/pharmacology
MH  - Indole Alkaloids/pharmacology
MH  - Male
MH  - Motor Activity/drug effects/physiology
MH  - Phosphorylation
MH  - Rats, Sprague-Dawley
MH  - Receptor, trkB/antagonists & inhibitors/*metabolism
MH  - *Vagus Nerve Stimulation/methods
PMC - PMC4817548
MID - NIHMS765169
OTO - NOTNLM
OT  - BDNF
OT  - TrkB
OT  - antidepressants
OT  - depression
OT  - desipramine
OT  - vagal nerve stimulation
EDAT- 2016/02/24 06:00
MHDA- 2016/12/15 06:00
PMCR- 2017/05/13
CRDT- 2016/02/23 06:00
PHST- 2015/11/01 00:00 [received]
PHST- 2016/01/23 00:00 [revised]
PHST- 2016/02/09 00:00 [accepted]
PHST- 2016/02/23 06:00 [entrez]
PHST- 2016/02/24 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
PHST- 2017/05/13 00:00 [pmc-release]
AID - S0306-4522(16)00147-0 [pii]
AID - 10.1016/j.neuroscience.2016.02.024 [doi]
PST - ppublish
SO  - Neuroscience. 2016 May 13;322:273-86. doi: 10.1016/j.neuroscience.2016.02.024. 
      Epub 2016 Feb 16.